来源:中国光谷12月23日,翰思艾泰生物医药科技(武汉)股份有限公司在港交所成功上市(股票代码:3378.HK),成为光谷第71家上市公司。翰思艾泰上市敲钟现场翰思艾泰成立于2014年,专注研发用于癌症及自身免疫疾病精准治疗的创新药。截至目前,公司拥有10款候选药物管线,其中3款处于临床阶段、7款处于临床前阶段。此次募集资金将主要投向产品研发。翰思艾泰核心产品HX009是全球唯一处于临床阶段的PD...
Source Link来源:中国光谷12月23日,翰思艾泰生物医药科技(武汉)股份有限公司在港交所成功上市(股票代码:3378.HK),成为光谷第71家上市公司。翰思艾泰上市敲钟现场翰思艾泰成立于2014年,专注研发用于癌症及自身免疫疾病精准治疗的创新药。截至目前,公司拥有10款候选药物管线,其中3款处于临床阶段、7款处于临床前阶段。此次募集资金将主要投向产品研发。翰思艾泰核心产品HX009是全球唯一处于临床阶段的PD...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.